The University of Southampton
University of Southampton Institutional Repository

The corporate social responsibility of pharmaceutical product recalls: An empirical examination of U.S. and U.K. markets

The corporate social responsibility of pharmaceutical product recalls: An empirical examination of U.S. and U.K. markets
The corporate social responsibility of pharmaceutical product recalls: An empirical examination of U.S. and U.K. markets

The pressure on companies to practice corporate social responsibility (CSR) has gained momentum in recent times as a means of sustaining competitive advantage in business. The pharmaceutical industry has been acutely affected by this trend. While pharmaceutical product recalls have become rampant and increased dramatically in recent years, no comprehensive study has been conducted to study the effects of announcements of recalls on the shareholder returns of pharmaceutical companies. As product recalls could significantly damage a company's reputation, profitability and brand integrity, this paper investigates the effect on shareholder wealth and the extent to which the adoption of CSR practices by pharmaceutical companies in the United Kingdom (U.K.) and the United States (U.S.), the two largest markets for pharmaceutical products in the world, affected market reactions surrounding product recall announcements. The analysis of product recall announcements from 1998 to 2004 compiled from The Pharmaceutical Journal and U.S. Food and Drug Administration enforcement reports revealed marked differences in the way market participants in the two countries responded to news of product recalls. U.S. investors penalised firms according to the severity of product defects while U.K. investors were indifferent. While U.K. investors rewarded product recalls by firms which were not usually CSR-active, U.S. investors punished non-CSR active firms that performed recalls. These observations could pose strategic challenges to pharmaceutical firms operating in both countries.

Corporate social responsibility, Pharmaceutical industry, Product recalls, Shareholder wealth, UK and US comparison
0167-4544
427-449
Cheah, Eng Tuck
298800de-521f-4aa8-9c04-2f58eece4c6e
Chan, Wen Li
325ea187-0750-47a4-adfa-a0b913010e8b
Chieng, Corinne Lin Lin
7d507141-d317-4564-a212-7bf06a4815e1
Cheah, Eng Tuck
298800de-521f-4aa8-9c04-2f58eece4c6e
Chan, Wen Li
325ea187-0750-47a4-adfa-a0b913010e8b
Chieng, Corinne Lin Lin
7d507141-d317-4564-a212-7bf06a4815e1

Cheah, Eng Tuck, Chan, Wen Li and Chieng, Corinne Lin Lin (2007) The corporate social responsibility of pharmaceutical product recalls: An empirical examination of U.S. and U.K. markets. Journal of Business Ethics, 76 (4), 427-449. (doi:10.1007/s10551-006-9292-1).

Record type: Article

Abstract

The pressure on companies to practice corporate social responsibility (CSR) has gained momentum in recent times as a means of sustaining competitive advantage in business. The pharmaceutical industry has been acutely affected by this trend. While pharmaceutical product recalls have become rampant and increased dramatically in recent years, no comprehensive study has been conducted to study the effects of announcements of recalls on the shareholder returns of pharmaceutical companies. As product recalls could significantly damage a company's reputation, profitability and brand integrity, this paper investigates the effect on shareholder wealth and the extent to which the adoption of CSR practices by pharmaceutical companies in the United Kingdom (U.K.) and the United States (U.S.), the two largest markets for pharmaceutical products in the world, affected market reactions surrounding product recall announcements. The analysis of product recall announcements from 1998 to 2004 compiled from The Pharmaceutical Journal and U.S. Food and Drug Administration enforcement reports revealed marked differences in the way market participants in the two countries responded to news of product recalls. U.S. investors penalised firms according to the severity of product defects while U.K. investors were indifferent. While U.K. investors rewarded product recalls by firms which were not usually CSR-active, U.S. investors punished non-CSR active firms that performed recalls. These observations could pose strategic challenges to pharmaceutical firms operating in both countries.

This record has no associated files available for download.

More information

e-pub ahead of print date: 17 March 2007
Published date: 1 December 2007
Keywords: Corporate social responsibility, Pharmaceutical industry, Product recalls, Shareholder wealth, UK and US comparison

Identifiers

Local EPrints ID: 431004
URI: http://eprints.soton.ac.uk/id/eprint/431004
ISSN: 0167-4544
PURE UUID: a311d374-fab9-4bd6-a8d4-a6129e918f58
ORCID for Eng Tuck Cheah: ORCID iD orcid.org/0000-0003-2953-3815

Catalogue record

Date deposited: 21 May 2019 16:30
Last modified: 16 Mar 2024 04:28

Export record

Altmetrics

Contributors

Author: Eng Tuck Cheah ORCID iD
Author: Wen Li Chan
Author: Corinne Lin Lin Chieng

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×